Aishat Bislieva - Boule Diagnostics VP Culture
| BOUL Stock | SEK 7.00 0.38 5.15% |
Insider
Aishat Bislieva is VP Culture of Boule Diagnostics AB
| Phone | 46 87 44 77 00 |
| Web | https://www.boule.com |
Boule Diagnostics Management Efficiency
The company has return on total asset (ROA) of 0.0271 % which means that it generated a profit of $0.0271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0335 %, meaning that it generated $0.0335 on every $100 dollars invested by stockholders. Boule Diagnostics' management efficiency ratios could be used to measure how well Boule Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Tim Thurn | C Rad AB | 42 | |
| MBA Econ | BioGaia AB | 73 | |
| Angelika Kjelldorff | BioGaia AB | 54 | |
| Hakan Axelsson | C Rad AB | 55 | |
| Maths hc | CellaVision AB | 57 | |
| Isabelle Ducellier | BioGaia AB | 54 | |
| CS BSc | Biotage AB | 50 | |
| Simon Ostergaard | CellaVision AB | 52 | |
| Lars LLB | Biotage AB | 62 | |
| Yve Thorenburg | CellaVision AB | 65 | |
| Peter Landquist | CTT Systems AB | 65 | |
| Urban Strindlov | CellaVision AB | 59 | |
| Jens Velling | BioGaia AB | N/A | |
| Tomas Blomquist | Biotage AB | 53 | |
| Markus Berg | CTT Systems AB | 43 | |
| Maria Wester | CTT Systems AB | 57 | |
| Scott Carr | Biotage AB | 56 | |
| Raffaella Bombarda | Biotage AB | 49 | |
| JonSverre Schanche | Biotage AB | 66 | |
| Julien Veyssy | CellaVision AB | 40 | |
| Tony Rosendal | CTT Systems AB | 56 | |
Management Performance
| Return On Equity | 0.0335 | |||
| Return On Asset | 0.0271 |
Boule Diagnostics Leadership Team
Elected by the shareholders, the Boule Diagnostics' board of directors comprises two types of representatives: Boule Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boule. The board's role is to monitor Boule Diagnostics' management team and ensure that shareholders' interests are well served. Boule Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boule Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annette Colin, VP CFO | ||
| Helena Borjesson, Chief Officer | ||
| Kiarash Farr, Director of Commercial Operations | ||
| Karen Bornstein, North Marketing | ||
| Aishat Bislieva, VP Culture | ||
| Jesper Soderqvist, CEO Pres | ||
| Mikael Ekholm, VP Production | ||
| Michael Eliott, Head Consumables | ||
| Mattias Isaksson, VP Marketing | ||
| Christina Hugosson, Head Systems |
Boule Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boule Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0335 | |||
| Return On Asset | 0.0271 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 562.26 M | |||
| Shares Outstanding | 38.83 M | |||
| Shares Owned By Insiders | 12.64 % | |||
| Shares Owned By Institutions | 27.69 % | |||
| Price To Earning | 24.26 X | |||
| Price To Book | 1.06 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Boule Stock Analysis
When running Boule Diagnostics' price analysis, check to measure Boule Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boule Diagnostics is operating at the current time. Most of Boule Diagnostics' value examination focuses on studying past and present price action to predict the probability of Boule Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boule Diagnostics' price. Additionally, you may evaluate how the addition of Boule Diagnostics to your portfolios can decrease your overall portfolio volatility.